Bretisilocin
chemical compound
Bretisilocin, also known by its developmental code name GM-2505 and as 5-fluoro-N-methyl-N-ethyltryptamine (5F-MET or 5-fluoro-MET), is a serotonergic psychedelic of the tryptamine family which is under development for the treatment of major depressive disorder. It is an analogue of dimethyltryptamine (DMT) and is the 5-fluorinated derivative of methylethyltryptamine (MET). Bretisilocin's route of administration is intravenous infusion.
The drug acts as a potent and well-balanced serotonin 5-HT2A and 5-HT2C receptor agonist, serotonin 5-HT2B receptor partial agonist or antagonist, and serotonin releasing agent. It produces psychedelic-like effects in animals and similarly produces robust hallucinogenic effects in humans. The duration of bretisilocin is 60 to 90 minutes and is intermediate between the durations of DMT and psilocybin. It has been regarded by its developer as an "improved version of DMT".
Bretisilocin was invented by Andrew Kruegel at Gilgamesh Pharmaceuticals and was patented in 2021. It is under development by Gilgamesh Pharmaceuticals. As of June 2025, the drug is in phase 2 clinical trials for the treatment of major depressive disorder.
“Bretisilocin” enters the record as chemical compound. Crown Archives preserves that source wording while asking what Bretisilocin, chemical and compound can confirm, complicate or overturn.
Why this record matters
“Bretisilocin” is worth following because a concise public description often conceals a longer documentary argument. Here, Bretisilocin, chemical and compound provides the most credible route into that argument.
The date and method of observation matter as much as the stated conclusion, especially where classification or consensus has changed. The source revision retrieved here is dated Sep 16, 2026. The linked authority identifier is Q110723043. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2021 and 2025.
Scientific names, classifications and consensus can change while older terminology persists in catalogues and historical literature. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.
- Current terminology
- Classification context
- Finding cited technical literature
Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.
Three-step research path
- Establish the record: confirm the title “Bretisilocin”, its source revision and the description used here.
- Expand the search: follow Bretisilocin primary sources, Bretisilocin archive and Bretisilocin research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Bretisilocin”?
- Which observation, specimen, dataset or publication supports the account?
- Has classification or technical consensus changed since the cited source?
Search terms from this dossier
This entry incorporates text from “Bretisilocin” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.